Healthcare Investment Banking: Groups & Deals
Healthcare investment banking explained: the pharma, biotech, medtech, and services subsectors, the deals each does, and how to prep for the interview.
May 14, 2026 · 7 min read
Healthcare investment banking is an industry group where bankers advise companies in the pharmaceutical, biotechnology, medical device, healthcare services, and healthcare IT markets on M&A, debt, and equity transactions. It's a single-industry group that executes every deal type, the opposite of a product group like M&A or leveraged finance that does one deal type across all industries. According to Mergers & Inquisitions, biopharma alone accounts for often over 75% of total healthcare market cap worldwide, so the group is large and the deal flow is steady. What makes healthcare specialized isn't the math, it's knowing the subsectors: how a drug gets to market, why a device's patent protection is weak, and how a hospital operator actually earns revenue.
TL;DR
- Healthcare IB is one industry group covering pharma, biotech, medtech, services, and healthcare IT, doing M&A, equity, and debt.
- Biopharma is often over 75% of total healthcare market cap worldwide (Mergers & Inquisitions).
- Drug development runs roughly 20 years and patent protection lasts around 20 years; medical-device exclusivity can be only 1 to 2 years.
- Biotech with no revenue is valued with a probability-weighted DCF; services firms use EV/EBITDA and per-bed metrics.
- Specialist banks (Leerink, Cain Brothers, Ziegler) compete with bulge brackets like JPM, GS, and MS.
What is healthcare investment banking?
Healthcare investment banking is the industry coverage group that advises healthcare companies on mergers and acquisitions, equity raises, and debt financing. Per Mergers & Inquisitions, bankers here serve biotech, pharmaceutical, medical device, healthcare service and facility, and healthcare IT clients on M&A, debt, and equity capital issuances. Because it's an industry group rather than a product group, a healthcare team runs the full deal menu (sell-side M&A, IPOs, follow-ons, convertible bonds, leveraged buyouts) but only for healthcare clients. The unifying skill is the sector knowledge: revenue models, regulation, and pipelines differ so much across subsectors that generalist coverage breaks down. That domain depth is what clients and interviewers are paying for.
What are the main healthcare subsectors?
Healthcare splits into a handful of subsectors with very different business models, and most groups organize their coverage around them. Mergers & Inquisitions groups them as biopharma (pharmaceuticals plus biotechnology), medical devices and equipment, healthcare services and facilities, and healthcare IT. Each behaves differently: biopharma lives and dies on drug pipelines, devices on incremental product cycles, services on volume and reimbursement, and IT on software adoption. You don't need a biology degree, but you do need to speak fluently about at least one subsector in interviews. The table below maps each one to its model, a representative metric, and example companies named by Mergers & Inquisitions.
| Subsector | Business model | Key metric | Example names |
|---|---|---|---|
| Pharma / Biotech | Drug R&D, patent-protected sales | Peak sales, probability of success | J&J, Pfizer, Amgen |
| Medical devices | Incremental device cycles | Procedure volume, share | Medtronic, Stryker, Boston Scientific |
| Healthcare services | Volume plus reimbursement | ALOS, revenue per bed | UnitedHealth, HCA, McKesson |
| Healthcare IT | Software adoption | Recurring revenue, telehealth growth | Mixed, often grouped with tech |
What deals does a healthcare group do?
A healthcare group executes the full transaction menu, just within one industry. Mergers & Inquisitions lists standard M&A, debt capital markets, equity capital markets, IPOs, and follow-ons, plus specialized structures that show up more often in healthcare: joint ventures, royalty arrangements, asset swaps, and spin-offs. Leveraged buyouts cluster in services and facilities, where cash flows are predictable enough to support debt. Convertible bonds are common in smaller biopharma because pre-revenue companies need financing without the cash cost of straight debt. Deal drivers per Mergers & Inquisitions include aging demographics, government reimbursement policy, and patent expirations forcing continuous M&A to refill pipelines. Named examples include Thermo Fisher's acquisition of Qiagen (with 2.2 billion dollars in senior notes) and KKR's leveraged buyout of Envision. For the broader map of coverage versus product groups, see investment banking groups explained.
How is valuation different in healthcare?
The methodologies are standard, but how you apply them shifts by subsector. Mergers & Inquisitions is blunt that, unlike commercial banks or insurers, healthcare has no huge accounting or modeling differences: you still run a DCF, comparable companies, precedent transactions, accretion/dilution, and LBO models. The twist is the inputs. A pre-revenue biotech is valued with a probability-weighted DCF, where projected drug cash flows are multiplied by the clinical-trial success probability at each phase, anchored to peak-sales estimates. Newer medtech companies increasingly borrow this no-revenue approach. Services and facilities lean on EV/EBITDA multiples and per-bed metrics like revenue per bed and average length of stay. The mechanics of the comparable company analysis and the walk me through a DCF framework are the same as any group; only the assumptions change.
What makes healthcare IB specialized?
Specialization comes from the subsector economics, not exotic finance. Three facts drive most of it. First, drug development takes roughly 10 years to develop plus another 10 to bring to market, with patent protection of around 20 years, so a "patent cliff" can erase a blockbuster's revenue overnight and force defensive M&A. Second, medical-device exclusivity can last only 1 to 2 years per Mergers & Inquisitions, so device firms compete on a faster product treadmill than pharma. Third, government reimbursement and FDA approval sit upstream of every revenue line, making policy a core part of any model. The sector is also less recession-proof than people assume: Mergers & Inquisitions notes roughly 1.4 million U.S. healthcare jobs were lost almost immediately in 2020 when elective procedures stopped. Knowing these mechanics is the real edge.
How do you prep for a healthcare IB interview?
Master the standard technicals first, then layer one subsector you can discuss with conviction. Wall Street Oasis stresses that interviewers care about genuine passion, so you should be able to speak about at least one healthcare subsector: how it makes money, whether it's capital intensive, the trends, and a recent M&A deal. You likely won't get healthcare-specific valuation math, the technicals mirror any other group, so the differentiator is sector fluency, not a special formula. Build the core toolkit through the investment banking technical interview questions bank, then prepare a sharp why investment banking answer that ties your interest to a real healthcare theme (a drug approval, a device launch, a services rollup). Read one biopharma deal and one services deal closely enough to discuss the rationale and rough multiple.
Frequently Asked Questions
Is healthcare investment banking a good group?
Yes, it's a strong group with broad skills and deep deal flow, since biopharma alone is often over 75% of healthcare market cap (Mergers & Inquisitions). You see the full transaction menu (M&A, IPOs, follow-ons, convertibles, LBOs) and build exit optionality into private equity, venture capital, hedge funds, and corporate development.
Do you need a science background for healthcare IB?
No. Mergers & Inquisitions states you do not need an advanced degree in medicine, biology, or chemistry, and undergrads from unrelated majors enter regularly. Knowledge of healthcare business models matters far more than lab science. You learn the clinical context on the job; the finance and the subsector economics are what get tested.
How do you value a pre-revenue biotech?
With a probability-weighted DCF. You project the drug's future cash flows from peak-sales estimates, then multiply them by the probability of clinical success at each trial phase, so the valuation reflects pipeline risk. Newer medtech companies with no early revenue increasingly use the same no-revenue methodology rather than standard EV/EBITDA multiples.
Which banks are strong in healthcare?
Bulge brackets like JPM, Goldman Sachs, and Morgan Stanley lead the big deals, while specialist firms dominate niches: Leerink, KeyBanc's Cain Brothers, Ziegler, and TripleTree. Mergers & Inquisitions notes no single bank dominates every vertical. Middle-market specialists like FOCUS, Houlihan Lokey, Harris Williams, and Baird handle smaller transactions.
What are the healthcare subsectors?
The main subsectors are biopharma (pharmaceuticals and biotechnology), medical devices and equipment, healthcare services and facilities, and healthcare IT. Mergers & Inquisitions groups them this way, and many banks split coverage further (therapeutics, tools and diagnostics, managed care). Each has a distinct revenue model, so most groups assign analysts to a specific vertical.
Is healthcare IB recession-proof?
Less than people assume. Mergers & Inquisitions says the sector held up well in the 2008 credit crisis since people still need hospitals and medicine, but it was hit hard in 2020 when elective procedures stopped, costing roughly 1.4 million U.S. healthcare jobs almost immediately. It's defensive in financial recessions, vulnerable in health crises.
Sources
- Mergers & Inquisitions: Healthcare Investment Banking Group (checked June 2026)
- FOCUS Investment Banking: Investment Banks for Healthcare Deals (checked June 2026)
- Wall Street Oasis: Healthcare Investment Banking Q&A (checked June 2026)